New biologics for treatment of chronic inflammatory bowel diseases;Neue biologika für die behandlung chronisch-entzündlicher darmerkrankungen

Internist

Volumn 55, Issue 4, 2014, Pages 367-376

  Schreiber, S ^a   Bachmann, O ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Crohn disease; Infliximab; Interleukin 6; Ulcerative colitis; Vedolizumab

Indexed keywords

BIOLOGICAL PRODUCT; CELL ADHESION MOLECULE; INTEGRIN; INTEGRIN ALPHA4BETA7; INTERLEUKIN 23; INTERLEUKIN 6; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; NEW DRUG;

BIOLOGICAL THERAPY; CROHN DISEASE; DRUG EFFICACY; REVIEW; TREATMENT INDICATION; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; DRUG APPROVAL; GERMANY; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC);

BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS, PHASE III AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; GERMANY; HUMANS; INTEGRINS; INTERLEUKIN-23;

EID: 84898538879     PISSN: 00209554     EISSN: 14321289     Source Type: Journal    
DOI: 10.1007/s00108-013-3415-4     Document Type: Review

References (53)

1. Allocca M, Jovani M, Fiorino G et al (2013) Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. Curr Drug Targets 14:1508-1521
2. Atreya R, Mudter J, Finotto S et al (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 6:583-588 (Pubitemid 30305911)
3. Best WR, Becktel JM, Singleton JW et al (1976) Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70:439-444
4. Candy S, Wright J, Gerber M et al (1995) A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37:674-678
5. Chalaris A, Adam N, Sina C et al (2010) Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med 207:1617-1624
6. Colombel JF, Sandborn WJ, Rutgeerts P et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132:52-65 (Pubitemid 46108762)
7. Duerr RH, Taylor KD, Brant SR et al (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:1461-1463 (Pubitemid 44871953)
8. EMA (2013) Zulassungsdossier Golimumab. EMA/619263/2013
9. Feagan BG, Rutgeerts P, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369:699-710
10. Genovese MC, Durez P, Richards HB et al (2013) Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 72:863-869
11. Gout T, Ostor AJ, Nisar MK (2011) Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 30:1471-1474
12. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359:1541-1549 (Pubitemid 34621118)
13. Henriksen M, Jahnsen J, Lygren I et al (2007) Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 42:602-610 (Pubitemid 46633816)
14. Hueber W, Sands BE, Lewitzky S et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61:1693-1700
15. Ito H, Takazoe M, Fukuda Y et al (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126:989-996 (Diskussion: 947)
16. Langholz E, Munkholm P, Davidsen M et al (1996) Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 31:260-266
17. Leonardi C, Matheson R, Zachariae C et al (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366:1190-1199
18. Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665-1674 (Pubitemid 351671883)
19. Lichtenstein GR, Thomsen OO, Schreiber S et al (2010) Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 8:600-609
20. Linsley PS, Brady W, Grosmaire L et al (1991) Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 173:721-730
21. Martin DA, Churchill M, Flores-Suarez L et al (2013) A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 15:R164
22. Panes J, Lopez-Sanroman A, Bermejo F et al (2013) Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 145:766-774.e761
23. Papp KA, Langley RG, Lebwohl M et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675-1684 (Pubitemid 351671884)
24. Papp KA, Langley RG, Sigurgeirsson B et al (2013) Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 168:412-421
25. Polman CH, O'Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
26. Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298:82-86
27. Rich P, Sigurgeirsson B, Thaci D et al (2013) Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 168:402-411
28. Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8:1237-1247
29. Sandborn WJ, Colombel JF, Enns R et al (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353:1912-1925 (Pubitemid 41565956)
30. Sandborn WJ, Colombel JF, Sands BE et al (2012) Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 143:62-69.e64
31. Sandborn WJ, Feagan BG, Marano C et al (2014) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:85-95
32. Sandborn WJ, Feagan BG, Marano C et al (2014) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:96-109.e101
33. Sandborn WJ, Feagan BG, Rutgeerts P et al (2013) Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369:711-721
34. Sandborn WJ, Gasink C, Gao LL et al (2012) Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367:1519-1528
35. Saverymuttu SH, Camilleri M, Rees H et al (1986) Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 90:1121-1128 (Pubitemid 16145475)
36. Scheller J, Garbers C, Rose-John S (2013) Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol (im Druck)
37. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al (2007) Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357:239-250 (Pubitemid 47080388)
38. Schreiber S, Nikolaus S, Malchow H et al (2001) Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 120:1339-1346 (Pubitemid 32322307)
39. Schreiber S, Rosenstiel P, Franke A (2014) Genetische Ätiologie bei chronisch-entzündlichen Darmerkrankungen. Internist (Berl) 55:156-164
40. Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625-1629 (Pubitemid 18010466)
41. Sieper J, Porter-Brown B, Thompson L et al (2014) Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 73:95-100
42. Smolen JS, Beaulieu A, Rubbert-Roth A et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987-997 (Pubitemid 351392039)
43. Sodenkamp J, Waetzig GH, Scheller J et al (2012) Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology 217:996-1004
44. Summers RW, Switz DM, Sessions JT Jr et al (1979) National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77:847-869 (Pubitemid 9242048)
45. Targan SR, Feagan BG, Vermeire S et al (2012) A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease. Gastroenterology 143:e26
46. Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353:362-368 (Pubitemid 41132340)
47. Deventer SJ van, Wedel MK, Baker BF et al (2006) A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 23:1415-1425
48. Vermeire S, Ghosh S, Panes J et al (2011) The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 60:1068-1075
49. Vermeire S, O'Byrne S, Williams M et al (2013) Differentiation between etrolizumab (Rhumab Beta7) and placebo in the EUCALYPTUS Phase II randomized double-blind placebo-controlled induction study to evaluate efficacy and safety in patients with refractory moderate-to-severely active ulcerative colitis. Gastroenterology 144:S-36
50. Waetzig GH, Rose-John S (2012) Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets 16:225-236
51. Westhovens R, Kremer JM, Moreland LW et al (2009) Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 36:736-742
52. Wyant T, Leach T, Sankoh S et al (2013) A phase 1, double-blind placebo-controlled single-dose study to determine the immune response to systemic and mucosal antigenic challenge in the presence of vedolizumab. J Crohns Colitis 7:248
53. Yacyshyn B, Chey WY, Wedel MK et al (2007) A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 5:215-220 (Pubitemid 46216935)